Planned Parenthood already mails abortion pills to women who have never seen a doctor in person.
Senate investigators asked the company that supplies those pills one simple question about its profits.
GenBioPro admitted abortion pills make up almost all its business, then refused to say how much it's worth.
Senate Committee Asked GenBioPro for a Mifepristone Spreadsheet and Got Stonewalled
The Senate Health, Education, Labor, and Pensions Committee wanted a simple answer.
Senators Bill Cassidy, Steve Daines, James Lankford, and Cindy Hyde-Smith asked GenBioPro for an Excel spreadsheet showing cost, revenue, and profit from mifepristone sales every quarter since 2019.
GenBioPro said no.
The company's lawyers at Arnold and Porter wrote back that mifepristone sales account for "the majority" of GenBioPro's revenue.
Senators pressed harder.
GenBioPro finally admitted the real number in June: 95 percent of its revenue comes from abortion pills.
Then the company drew the line.
Anything more specific, GenBioPro said, would disclose "commercially sensitive business information."
This is the same company the FDA allowed to become America's sole supplier of generic mifepristone, and it sold more than 850,000 units between 2019 and 2023 alone.
GenBioPro will tell Congress what percentage of its business is abortion, just not how much money that percentage actually is.
The Math That Suggests GenBioPro Is Pocketing Millions From Mifepristone Sales
GenBioPro would not hand over real numbers, but the outlines are there.
Moody's Cortera business database estimates GenBioPro's total revenue somewhere between $10 million and $25 million.
Run the math on the 95 percent GenBioPro admitted to, and that comes out to between $9.5 million and $23.75 million a year from abortion pills alone.
Danco Laboratories, the original Mifeprex maker, told the same committee it once made nearly $20 million a year from it alone.
Abortion industry insiders are now pushing an unapproved one-drug regimen with misoprostol alone, which could push revenue higher.
GenBioPro Says It Has Never Punished a Pharmacy Over Mifepristone Safety Rules
Every mifepristone sale is supposed to come with a safety net: REMS, the FDA's rules for catching prescribers and pharmacies that break them.
GenBioPro told the Senate committee it has never decertified a single certified prescriber or pharmacy since generic mifepristone launched in 2019.
Not once, in seven years, while the company supplied roughly two-thirds of America's abortion pills in 2023.
Shanyce Thomas knows what happens when that safety net fails, even under the old rules.
At 19, Thomas took mifepristone after an ultrasound and in-person counseling, the very oversight regulators are now stripping away.
She retained pregnancy tissue, went into septic shock, and spent a month and a half in a coma while doctors fought to save her life.
"The pain quickly became unbearable," Thomas later wrote. "I could barely move."
Physicians at the Charlotte Lozier Institute, including Dr. Ingrid Skop, warn that stripping away exams like hers is "certain to harm, rather than improve, women's health."
Planned Parenthood, linked directly from GenBioPro's patient resources page, advertises selling abortion drugs "just in case" a woman becomes pregnant later – a marketing practice Live Action News has documented as falling outside REMS requirements.
GenBioPro's answer was to disclaim any control over what Planned Parenthood publishes about its product.
National Right to Life president Carol Tobias called the system exactly what it looks like: "This report exposes an abortion-pill system built on secrecy, self-policing, and astonishingly little accountability."
Tobias also flagged a detail Democrats do not like to discuss: the FDA scrapped mandatory adverse event reporting for mifepristone back in 2016, and reported injuries dropped immediately afterward.
"An absence of reports is not evidence of an absence of injuries," Tobias said, "especially when the reporting requirement itself has been removed."
The Pro-Abortion Foundations Bankrolling GenBioPro's Abortion Pill Business
GenBioPro did not build this business alone.
The pro-abortion David and Lucile Packard Foundation helped seed the company from the start.
ReproHub, led by a Planned Parenthood Online co-founder, sent GenBioPro a $3.7 million grant in 2024.
George Soros's Economic Fund listed $3 million in assets tied to GenBioPro across 2023 and 2024.
When the Washington Free Beacon asked whether Packard stands to profit if GenBioPro's value rises, the foundation pointed to a statement admitting it invests "in pursuit of impact while seeking overall return of principal" so it can "recycle capital."
Translation: the same pro-abortion donors bankrolling GenBioPro's growth expect their money back, with interest, from a company that will not say how much it earns.
The APPLE Act Pro-Life Advocates Say Could Fix Mail-Order Abortion Pill Oversight
Congress cannot force GenBioPro's spreadsheet, but senators do not need its help.
Josh Hawley is already demanding the same kind of records from both Danco Laboratories and GenBioPro, warning that mifepristone causes "hemorrhage, infection, sepsis, and other dangerous complications" while manufacturers keep collecting checks.
Tobias and National Right to Life are pushing states to adopt the APPLE Act – the Abortion Pill Provider Liability and Education Act – a law that would give women and law enforcement a real paper trail when something goes wrong with a mail-order abortion pill.
"Women deserve more than a website, a package in the mail, and instructions to go to the emergency room if something goes wrong," Tobias said.
GenBioPro built a business worth tens of millions of dollars on a drug the FDA calls dangerous enough to require special safety rules, then ignored those rules for seven years.
Congress now knows exactly how much of GenBioPro's business is abortion.
Sooner or later, they are going to find out exactly how much money it is too.
Sources:
- Carole Novielli, "'Without Guardrails': Abortion Pill Manufacturer Refuses to Disclose Revenue," Live Action News, September 2026.
- Senate Health, Education, Labor, and Pensions Committee, "Mifepristone Without Guardrails: An Investigation Into How Chemical Abortion Drug Makers Are Putting Mothers and Babies At Risk," U.S. Senate HELP Committee, August 2026.
- National Right to Life, "NRL Praises Senate HELP Committee for Exposing Dangerous Gaps in Abortion Pill Oversight," National Right to Life, 2026.
- "Hawley Launches Investigation Into Abortion Drug Manufacturers Over Grave Risks to Women," Fox News, 2026.
- Amy Curtis, "Congressional Report Exposes How Chemical Abortion Drug Companies Endanger Mothers," Townhall, August 27, 2026.
- Shanyce Thomas, "I Nearly Died After Taking Abortion Drugs — They Don't Belong in the Mail," The Hill, May 2026.
- David C. Reardon et al., "Overlooked Dangers of Mifepristone, the FDA's Reduced REMS, and Self-Managed Abortion Policies," Charlotte Lozier Institute, 2026.
